No RCTs were found. Interleukin (IL)-2 (20 MU/m2 every 2 weeks for 6 weeks and then monthly for 5 months) produced responses in five of seven CTCL patients, including CR in three.40
In a phase I dose-escalation study of subcutaneous IL-12 (50-300 ng/kg) twice weekly for up to 24 weeks, objective responses were noted in five CTCL patients (4/5 with stage IB disease; 1/3 with Sezary syndrome).41 Two patients with stage IB disease had a CR within 7-8 weeks, which was confirmed histologically. Intralesional therapy was also effective for individual tumours in two patients with stage IIB disease, but both developed progressive disease.41
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.